The latest announcement is out from GlaxoSmithKline ( (GB:GSK) ).

Dame Emma Walmsley will step down as GSK’s chief executive at the end of the year, concluding nine years at the helm of Britain’s second-largest pharmaceuticals company.

The shares of GlaxoSmithKline ($GSK) cheered on Monday after the British pharmaceutical giant announced that its chief ...

GSK named Luke Miels to succeed Emma Walmsley as the British drugmaker’s CEO. - chris j ratcliffe/Reuters GSK said Emma ...

The new projects, including AI efforts in Pennsylvania and three other states, are part of the British firm's pledge to ...

GSK plc (NYSE:GSK) plc Bank of America Global Healthcare Conference 2025 September 24, 2025 4:00 AM EDTCompany ParticipantsJulie Brown - CFO & ...

GSK commits $30 billion investment in U.S. R&D and manufacturing during Trump’s UK state visit, strengthening its focus on ...

GlaxoSmithKline (GSK) and Eli Lilly are making major U.S. manufacturing commitments as global pharmaceutical companies expand ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as ...

In a report released today, Luisa Hector from Berenberg Bank maintained a Hold rating on GlaxoSmithKline, with a price target of £16.00. The company’s shares opened today at p1,464.00. Take advantage ...

Emma Walmsley, GSK's CEO, will be replaced by Luke Miels, the chief commercial officer, after almost nine years in the role.